Biohaven (BHVN) Stock Price, News & Analysis

Company Overview

Biohaven Ltd. is a clinical-stage biopharmaceutical company developing treatments for neurological, immunological and other serious diseases. Its research programs include potential therapies for epilepsy and autoimmune conditions, as well as medicines designed to target disease-related proteins and antibodies.

The company’s pipeline includes investigational candidates that act on ion channels and immune pathways. These programs are in development and are not approved medicines; Biohaven does not have a marketed product portfolio.

Biohaven Ltd. was formed in 2022 after Pfizer acquired the former Biohaven Pharmaceutical, whose migraine drug Nurtec ODT became part of Pfizer’s business. The current company is led by founder and Chief Executive Officer Vlad Coric and is based in New Haven, Connecticut.

Key Stats

• Today's Range: $13.37 to $14.29
• 50-Day Range: $10.83 to $16.45
• 52-Week Range: $7.81 to $18.24
• Volume: 349,880 shs
• Average Volume: 2.76 million shs
• Market Capitalization: $2.08 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.80
• Consensus Rating: Moderate Buy

Biohaven Stock Analysis - MarketRank™

Biohaven scored higher than 74% of companies evaluated by MarketBeat, and ranked 154th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Biohaven has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 2 strong buy ratings, 8 buy ratings, 4 hold ratings, and 2 sell ratings.

Upside Potential

Biohaven has a consensus price target of $20.80, representing about 50.8% upside from its current price of $13.80.

Amount of Analyst Coverage

Biohaven has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Biohaven are expected to grow in the coming year, from ($2.99) to ($2.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Biohaven is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biohaven is -3.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.53% of the float of Biohaven has been sold short.

Short Interest Ratio / Days to Cover

Biohaven has a short interest ratio ("days to cover") of 2.94, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biohaven has recently decreased by 16.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biohaven does not currently pay a dividend.

Dividend Growth

Biohaven does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.09

News Sentiment

Biohaven has a news sentiment score of -0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Biohaven this week, compared to 4 articles on an average week.

Search Interest

18 people have searched for BHVN on MarketBeat in the last 30 days. This is an increase of 260% compared to the previous 30 days.

MarketBeat Follows

2 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biohaven insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.80% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:BHVN
• Previous Symbol: NASDAQ:BHVN
• CIK: 1935979
• Web: www.biohaven.com
• Phone: 203-404-0410
• Fax: N/A
• Employees: 274
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Biohaven: $20.80
• High Price Target: $48.00
• Low Price Target: $10.00
• Potential Upside/Downside: +52.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$738.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -2,271.88%
• Return on Assets: -139.84%

Debt

• Debt-to-Equity Ratio: 21.23
• Current Ratio: 3.05
• Quick Ratio: 3.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.65) per share
• Price / Book: -20.98

Miscellaneous

• Outstanding Shares: 151,060,000
• Free Float: 130,213,000
• Market Cap: $2.06 billion
• Optionable: Optionable
• Beta: 1.36